Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year Destiny Pharma’s XF platform is delivering effective drug candidates that also address the threat of AMR Brighton, United Kingdom, 21 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]
The Hague, Netherlands, 19 January 2022: Amber Implants, an innovative medical technology company developing next generation spinal implants for spinal injuries, today announces the successful closing of its US$10 million Series A Financing in 2021. The round was co-led by the founders and existing venture capital investors, with participation from angel investors and non-dilutive government funding. […]
Emcitate® (tiratricol) is the first potential treatment of MCT8 deficiency, a rare genetic disease with high unmet medical need and no available treatment. Egetis will host a webcast today at 15:00 CET (9:00am ET) Stockholm, Sweden, January 18, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) (the “Company”) today announced that in recent regulatory interactions, […]
Brighton, United Kingdom, 17 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces today an update on the considerable progress being made with its late-stage clinical assets, its earlier research programmes and the exciting prospects for the […]
Over US$ 550 million raised by portfolio companies in 2021 IO Biotech IPO on US NASDAQ Forendo Pharma acquired for nearly US$ 1 billion Muna launched with world-leading science to advance latest scientific breakthroughs in neuroscience Adcendo raised US$ 60 million Series A to deliver next-generation Antibody-Drug Conjugates Hemab raised US$ 50 million Series A to […]
